Why the study?
Does interferon-alpha or thymomodulin added to conventional therapy improve left ventricular function in patients with idiopathic myocarditis and idiopathic dilated cardiomyopathy?
Does interferon-alpha or thymomodulin added to conventional therapy improve left ventricular function in patients with idiopathic myocarditis and idiopathic dilated cardiomyopathy?
Immunomodulatory therapy with interferon-alpha or thymomodulin may improve left ventricular function and clinical outcomes in patients with myocarditis and idiopathic dilated cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Supports immunomodulator addition in idiopathic myocarditis or dilated cardiomyopathy; extends RCT evidence on LV reserve beyond conventional therapy alone.
It is becoming increasingly apparent that idiopathic dilated cardiomyopathy (IDC) probably results from an acute viral myocarditis. One reasonable hypothesis is that persistent viral infection causes myocardial destruction leading to left ventricular dilatation and heart failure. The aim of this study was to evaluate the efficacy of interferon-alpha (IFN) and thymomodulin in the treatment of idiopathic myocarditis and IDC. Clinical, immunological, haemodynamic and histological evaluation was performed in 40 patients before inclusion in the study. Patients were randomized into three treatment groups: (a) conventional therapy plus IFN, (b) conventional therapy plus thymomodulin and (c) conventional therapy alone. Two-year follow-up included repeated endomyocardial biopsy, echocardiographic evaluation, treadmill exercise test, Holter monitoring study and radionuclide assessment of left ventricular function during exercise. Left ventricular ejection fraction increased during follow-up in most of the IFN-and thymomodulin-treated patients, and only in a few of conventionally treated patients. Left ventricular reserve was significantly higher at 2-year follow-up in patients treated with immunomodulators. No serious adverse effects were noticed during treatment. Our results suggest that treatment of myocarditis and/or IDC with IFN or thymomodulin induces an earlier and significantly superior clinical improvement than conventional therapy alone.
No takes yet. Share an insight, caveat, or question.
Miric et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: